Journal
PARASITOLOGY RESEARCH
Volume 117, Issue 2, Pages 355-363Publisher
SPRINGER
DOI: 10.1007/s00436-017-5698-1
Keywords
Anti-parasitic; Drug discovery; FDA-approved compounds; Natural products; Toxoplasmosis
Categories
Funding
- JSPS Fellowship
- Ministry of Education, Culture, Science, Sports, and Technology (MEXT) of Japan [3308, 3407]
- Ito Foundation
- Grants-in-Aid for Scientific Research [16KT0141, 15F15098, 3407] Funding Source: KAKEN
Ask authors/readers for more resources
Toxoplasma gondii is the etiological agent of toxoplasmosis, a common parasitic disease that affects nearly one-third of the human population. The primary infection can be asymptomatic in healthy individuals but may prove fatal in immunocompromised individuals. Available treatment options for toxoplasmosis patients are limited, underscoring the urgent need to identify and develop new therapies. Non-biased screening of libraries of chemical compounds including the repurposing of well-characterized compounds is emerging as viable approach to achieving this goal. In the present investigation, we screened libraries of natural product and FDA-approved compounds to identify those that inhibited T. gondii growth. We identified 32 new compounds that potently inhibit T. gondii growth. Our findings are new and promising, and further strengthen the prospects of drug repurposing as well as the screening of a wide range of chemical compounds as a viable source of alternative anti-parasitic therapeutic agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available